Shao YHJ, et al. - In patients without viral hepatitis B or C, researchers investigated whether long-term proton pump inhibitor (PPI) use increases the risk of hepatocellular carcinoma (HCC) via conducting a nested case-control study in a cohort of patients without viral hepatitis in Taiwan from 2000 to 2013. For this investigation, they involved 29,473 HCC cases and 294,508 matched controls. It was observed that the adjusted odds ratio (AOR) for HCC associated with PPI use was 2.86. The findings from the present study suggested that PPIs might increase the risk of HCC.